# NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

* The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE Therapeutics, is expected to be immediately accretive to revenue and EBITDA.
* Cohen, serving the Sarasota-Bradenton area in Florida, specializes in treatments, including ketamine and TMS, for mood disorders, PTSD, and suicidal depression.
* HOPE Therapeutics is expanding toward a target of 30 clinics with a $100 million run rate by the end of 2025.

 NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary HOPE Therapeutics, Inc., a multi-site clinical care delivery organization, recently signed a binding letter of intent to acquire a 49% stake in Cohen and Associates, LLC, a respected neuropsychiatry clinic based in western Florida (https://ibn.fm/geIxF).

 The agreement, announced on June 26, positions Cohen as a foundational clinic in the Sarasota-Bradenton region for HOPE’s growing network. Cohen and Associates, led by Dr. Rebecca Cohen, offers a comprehensive range of psychiatric care options, including ketamine infusions, Spravato, transcranial…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/nrx-pharmaceuticals-inc-nasdaq-nrxp-subsidiary-to-acquire-49-stake-in-prominent-florida-neuropsychiatry-clinic/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nrx-pharmaceuticals-expands-mental-health-footprint-with-florida-clinic-acquisition/62a7c5816238b7f4956db7760f6c219b) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1lup214/nrx_pharmaceuticals_expands_mental_health/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/8/hint7LOR.webp)